These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 30509990)

  • 21. Pathology-associated change in levels and localization of SIDT2 in postmortem brains of Parkinson's disease and dementia with Lewy bodies patients.
    Fujiwara Y; Kabuta C; Sano T; Murayama S; Saito Y; Kabuta T
    Neurochem Int; 2022 Jan; 152():105243. PubMed ID: 34800582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
    Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
    Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss.
    Grigoletto J; Pukaß K; Gamliel A; Davidi D; Katz-Brull R; Richter-Landsberg C; Sharon R
    Acta Neuropathol Commun; 2017 May; 5(1):37. PubMed ID: 28482862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human amyloid beta and α-synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in Caenorhabditis elegans.
    Huang X; Wang C; Chen L; Zhang T; Leung KL; Wong G
    Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166203. PubMed ID: 34146705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology.
    Tsuboi Y; Uchikado H; Dickson DW
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S221-4. PubMed ID: 18267239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphorylated NUB1 distinguishes α-synuclein in Lewy bodies from that in glial cytoplasmic inclusions in multiple system atrophy.
    Tanji K; Miki Y; Mori F; Kon T; Kakita A; Takahashi H; Wakabayashi K
    Brain Pathol; 2019 Nov; 29(6):803-812. PubMed ID: 31006160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.
    Sharon R; Bar-Joseph I; Frosch MP; Walsh DM; Hamilton JA; Selkoe DJ
    Neuron; 2003 Feb; 37(4):583-95. PubMed ID: 12597857
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Dutta AK; Armstrong C; Luo D; Das B; Spencer B; Rissman RA
    ACS Chem Neurosci; 2023 Mar; 14(5):885-896. PubMed ID: 36749600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein.
    Sekigawa A; Fujita M; Sekiyama K; Takamatsu Y; Hatano T; Rockenstein E; La Spada AR; Masliah E; Hashimoto M
    Mol Brain; 2012 Sep; 5():34. PubMed ID: 23013868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of NUB1 in α-synuclein degradation in Lewy body disease model mice.
    Tanji K; Miki Y; Maruyama A; Mori F; Mimura J; Itoh K; Kamitani T; Wakabayashi K
    Biochem Biophys Res Commun; 2016 Feb; 470(3):635-642. PubMed ID: 26797281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Path mediation analysis reveals GBA impacts Lewy body disease status by increasing α-synuclein levels.
    Gündner AL; Duran-Pacheco G; Zimmermann S; Ruf I; Moors T; Baumann K; Jagasia R; van de Berg WDJ; Kremer T
    Neurobiol Dis; 2019 Jan; 121():205-213. PubMed ID: 30236861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.
    Spencer B; Michael S; Shen J; Kosberg K; Rockenstein E; Patrick C; Adame A; Masliah E
    Mol Ther; 2013 Jan; 21(1):31-41. PubMed ID: 22508489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
    Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
    Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathological biochemistry of alpha-synucleinopathy.
    Iwatsubo T
    Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid.
    Asam K; Staniszewski A; Zhang H; Melideo SL; Mazzeo A; Voronkov M; Huber KL; Pérez E; Stock M; Stock JB; Arancio O; Nicholls RE
    PLoS One; 2017; 12(12):e0189413. PubMed ID: 29253878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.